The APOE4 genetic test identifies whether you carry the apolipoprotein E ε4 variant, which increases dementia risk, and achieves complete analytical accuracy through blood or saliva analysis. The test's real value depends on whether you have symptoms or are eligible for treatment—it offers useful information in some situations and creates uncertainty in others where no proven prevention exists.
APOE4 exists in three forms (ε2, ε3, ε4), and each person carries two copies. Testing identifies which copies you have, typically with results in 5–7 business days. But because the test is neither necessary nor sufficient for Alzheimer's disease—half of diagnosed patients carry ε4, half do not— the test's meaning depends on whether you're healthy, have mild memory problems, or show dementia symptoms.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Much Risk Does APOE4 Actually Confer?
- What Does It Cost and When Is It Covered?
- Critical Limits on What This Test Tells You
- When APOE4 Testing Actually Changes Your Care
- The Shift Toward Routine Testing in Asymptomatic People
- Frequently Asked Questions
How Much Risk Does APOE4 Actually Confer?
Your dementia risk from APOE4 depends on how many copies you carry. According to the National Institute on Aging, carriers of one ε4 copy face 3–4 times higher dementia risk than people with two ε3 copies (the most common type). Homozygotes—people with two ε4 copies—face 8–12 times higher risk.
Yet having the gene does not mean you will develop dementia. Roughly 30% of ε4 carriers over age 80 show no cognitive decline or Alzheimer's pathology at all. This wide variation means genetic risk is only part of the picture; other factors like education, cardiovascular health, cognitive engagement, and sleep also influence whether dementia develops.
What Does It Cost and When Is It Covered?
Direct-to-consumer testing costs $184–$250 at labs like TestWell and Quest Direct. If ordered through a hospital or clinic, the same test may cost $600 or more.
Most insurance plans do not cover apoe4 testing in asymptomatic people—that is, people without memory problems or cognitive symptoms—making this a potential out-of-pocket expense. If you have a doctor's order, insurance is more likely to cover the test, especially if you show early cognitive symptoms. Check your plan before ordering, as coverage varies widely by insurer and whether cognitive decline is already present.
Critical Limits on What This Test Tells You
Two major limitations make APOE4 testing less useful for healthy people than the marketing suggests. First, ancestry bias limits the test's applicability across diverse populations—the association between APOE4 and dementia risk is strongest in White and Caucasian populations, with smaller or imprecise risk estimates in other racial and ethnic groups. This means the risk percentages cited above apply most reliably to European ancestry populations and less reliably to others. Second, and more consequential, standard Alzheimer's disease medications do not reduce dementia risk in asymptomatic ε4 carriers, making the clinical utility of testing in healthy individuals questionable outside specific contexts. Knowing you carry ε4 does not change what you can do to prevent dementia in the absence of already-present cognitive symptoms.
When APOE4 Testing Actually Changes Your Care
The primary reason clinicians order APOE4 testing today is to determine safety before prescribing anti-amyloid monoclonal antibody therapy. FDA-approved anti-amyloid drugs like lecanemab and donanemab are indicated only for mild cognitive impairment or mild dementia, and APOE4 status determines whether these drugs are safe for you.
If you carry two ε4 copies (ε4/ε4), lecanemab carries a 32.6% risk of amyloid-related imaging abnormality (ARIA)—brain swelling or microhemorrhages—more than three times higher than in non-carriers, and lecanemab is contraindicated in this group by major treatment guidelines. In trials, ε4/ε4 homozygotes also showed greater cognitive decline on lecanemab than on placebo. For this population, the drug's risks outweigh benefits.
The Shift Toward Routine Testing in Asymptomatic People
Clinical guidance on APOE4 testing is changing. 2026 publications advocate expanding access to testing in asymptomatic populations due to FDA-approved therapies, low adverse psychological outcomes, and aging populations seeking risk knowledge, reversing decades of caution against routine predictive testing. This represents a meaningful shift from the prior consensus that testing was inadvisable in healthy people without cognitive symptoms.
Genetic counseling before and after testing is strongly recommended, however, due to psychological and ethical implications. Having a genetic risk factor can affect self-image, family planning decisions, and insurance or employment concerns in some jurisdictions—issues worth discussing with a counselor or genetic specialist before deciding to test.
- —
Frequently Asked Questions
Should I get tested if I have no symptoms?
Testing is most useful if you have mild cognitive impairment or mild dementia and are considering anti-amyloid therapy. In asymptomatic people, knowing your status may increase anxiety without offering preventive options, though this is changing as more therapies enter the market.
What if I'm ε4/ε4 positive and my doctor recommends lecanemab?
Lecanemab is contraindicated in ε4/ε4 homozygotes due to high ARIA risk. Request a different anti-amyloid drug or ask whether anti-amyloid therapy is appropriate for you at all.
Will my insurance cover the test?
Coverage depends on whether you have cognitive symptoms and your plan. Direct-to-consumer testing costs $184–$250 out of pocket if insurance declines.
